KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $24.0 million.

  • Rigel Pharmaceuticals' Cash from Operations rose 1084.92% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.2 million, marking a year-over-year increase of 53551.45%. This contributed to the annual value of $31.5 million for FY2024, which is 64798.89% up from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' Cash from Operations is $24.0 million, which was up 1084.92% from $30.5 million recorded in Q2 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Cash from Operations peaked at $55.2 million during Q2 2021, and registered a low of -$25.6 million during Q1 2022.
  • Its 5-year average for Cash from Operations is $606473.7, with a median of -$4.1 million in 2023.
  • Per our database at Business Quant, Rigel Pharmaceuticals' Cash from Operations crashed by 54516.65% in 2021 and then skyrocketed by 1001158.94% in 2025.
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' Cash from Operations stood at -$19.1 million in 2021, then decreased by 14.79% to -$21.9 million in 2022, then soared by 71.52% to -$6.2 million in 2023, then skyrocketed by 332.42% to $14.5 million in 2024, then surged by 65.7% to $24.0 million in 2025.
  • Its Cash from Operations was $24.0 million in Q3 2025, compared to $30.5 million in Q2 2025 and -$893000.0 in Q1 2025.